Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2095668
Abstract: Abstract Introduction There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. Methods We retrieved the full datasets of two observational, multicentre,… read more here.
Keywords: vedolizumab; ulcerative colitis; clinical remission; vedolizumab ustekinumab ... See more keywords
P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.510
Abstract: In 2018, our Trust approved the use of vedolizumab in children with Ulcerative Colitis (UC) and ustekinumab in children with Crohn’s Disease (CD). At the time, access to these drugs for children was only possible… read more here.
Keywords: vedolizumab ustekinumab; p386 two; treated vedolizumab; two year ... See more keywords
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2022.37.e107
Abstract: The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical… read more here.
Keywords: tuberculosis patients; vedolizumab ustekinumab; tuberculosis; disease ... See more keywords